Thursday, October 15, 2026

Corn Futures Went Down By Over 9% In The Last 21 Sessions

Corn Futures Went Down By Over 9% In The Last 21 Sessions

(VIANEWS) - Corn (ZC) has been up by 9.28% for the last 21 sessions. At 22:52 EST on Saturday, 11 March, Corn (ZC) is $618.25.

Volume

Today's last reported volume for Corn is 128906, 5.85% above its average volume of 121781.48.

Volatility

Corn's last week, last month's, and last quarter's current intraday variation average was a positive 0.37%, a negative 0.37%, and a positive 0.94%, respectively.

Corn's highest amplitude of average volatility was 0.66% (last week), 0.84% (last month), and 0.94% (last quarter), respectively.

Commodity Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Corn's commodity is considered to be overbought (>=80).

News about

  • Crude oil forecast: still looks somewhat lost - 10 March 2023. According to DailyForex on Friday, 10 March, "The WTI Crude Oil market experienced a bit of a rally during Thursday's trading session but remains stuck in a range due to a lot of back-and-forth noisy behavior. ", "Until the market breaks out of its current range, traders should assume that it will continue to move back and forth between the $72.50 and $82.50 levels for the WTI Crude Oil market and the $77.50 and $89 levels for the Brent market. "
  • According to FXStreet on Friday, 10 March, "The selling pressure around Crude Oil prices remains unabated for the fourth straight day, which undermines the commodity-linked Loonie and acts as a tailwind for the USD/CAD pair. "

More news about Corn (ZC).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com